Assignee
NANTBIO INC
US·43 granted patents·36 pending applications·44 citations·filing 2016–2025
Top patents by PatentIndex Score
79 records- 0193US10724043B2Multi-pulse transfection methods and cellsNANTBIO INC·Filed 2017·Granted Jul 28, 2020·21 cites·17 claims
- 0292US11753467B2Anti-TIM3 monoclonal antibodies and chimeric antigen receptorsNANTBIO INC·Filed 2022·Granted Sep 12, 2023·2 cites·20 claims
- 0392US11298414B2Cellular adjuvants for viral infectionNANTBIO INC·Filed 2019·Granted Apr 12, 2022·6 cites·8 claims
- 0491US10814011B1Anti-B7-H4 antibodies and methodsNANTBIO INC·Filed 2018·Granted Oct 27, 2020·7 cites·26 claims
- 0589US12350323B2Cellular adjuvants for viral infectionNANTBIO INC·Filed 2024·Granted Jul 8, 2025·0 cites·18 claims
- 0688US12329809B2Cellular adjuvants for viral infectionNANTBIO INC·Filed 2024·Granted Jun 17, 2025·0 cites·18 claims
- 0788US2025369959A1Live Cell Imaging Systems & Methods of UseNANTBIO INC·Filed 2025·Application pending·0 cites
- 0886US11034951B2mRNA display antibody library and methodsNANTBIO INC·Filed 2019·Granted Jun 15, 2021·2 cites·7 claims
- 0984US12263189B2Mesenchymal stem cell derived exosomes and methodsNANTBIO INC·Filed 2019·Granted Apr 1, 2025·1 cites·7 claims
- 1084US10752682B2Anti-IL8 antibodiesNANTBIO INC·Filed 2018·Granted Aug 25, 2020·2 cites·10 claims
- 1183US11015188B2MRNA display antibody library and methodsNANTBIO INC·Filed 2018·Granted May 25, 2021·2 cites·13 claims
- 1282US12416635B2Live cell imaging systems and methods to validate triggering of immune responseNANTBIO INC·Filed 2022·Granted Sep 16, 2025·0 cites·13 claims
- 1382US2024263355A1mRNA display antibody library and methodsNANTBIO INC·Filed 2024·Application pending·0 cites
- 1481US12397019B2Mesenchymal stem cell derived exosomes and methodsNANTBIO INC·Filed 2024·Granted Aug 26, 2025·0 cites·8 claims
- 1581US2025262288A1Cellular Adjuvants for Viral InfectionNANTBIO INC·Filed 2025·Application pending·0 cites
- 1679US12220452B2Cellular adjuvants for viral infectionNANTBIO INC·Filed 2022·Granted Feb 11, 2025·0 cites·19 claims
- 1779US12098201B2Anti-TIM3 monoclonal antibodies and chimeric antigen receptorsNANTBIO INC·Filed 2023·Granted Sep 24, 2024·0 cites·19 claims
- 1879US2024209384A1Multi-Pulse Transfection Methods And CellsNANTBIO INC·Filed 2024·Application pending·0 cites
- 1979US2023230654A1Validation of inferred anticancer pathwaysNANTBIO INC·Filed 2023·Application pending·0 cites
- 2079US2024336684A1Anti-TIM3 monoclonal antibodies and chimeric antigen receptorsNANTBIO INC·Filed 2024·Application pending·0 cites
- 2178US12247086B2Enhanced immunogenicity for GPI-anchored antigensNANTBIO INC·Filed 2023·Granted Mar 11, 2025·0 cites·18 claims
- 2277US2024294875A1Reprogrammed T Cell-Like NK CellsNANTBIO INC·Filed 2024·Application pending·0 cites
- 2377US2024350603A1Method Of Validating The Triggering Of An Immune Response To A Neoepitope Of A Tumor With T-CellsNANTBIO INC·Filed 2024·Application pending·0 cites
- 2477US2024190945A1mRNA display antibody library and methodsNANTBIO INC·Filed 2023·Application pending·0 cites
- 2576US2023406918A1Method of treatment of a tumor with il-8 antibodyNANTBIO INC·Filed 2023·Application pending·0 cites
- 2674US2024360191A1Targeted IL-12 Treatments and Methods to Stimulate haNK and NK92mi CellsNANTBIO INC·Filed 2024·Application pending·0 cites
- 2774US2024272141A1Interferometry Based Systems To Detect Small Mass Changes Of An Object In a SolutionNANTBIO INC·Filed 2024·Application pending·0 cites
- 2873US12060655B2mRNA display antibody library and methodsNANTBIO INC·Filed 2021·Granted Aug 13, 2024·0 cites·7 claims
- 2973US2023270879A1Anti-B7-H4 Antibodies And MethodsNANTBIO INC·Filed 2023·Application pending·0 cites
- 3071US11912756B2MRNA display antibody library and methodsNANTBIO INC·Filed 2021·Granted Feb 27, 2024·0 cites·5 claims
- 3171US10344026B2Compositions and methods of targeting mutant K-rasNANTBIO INC·Filed 2018·Granted Jul 9, 2019·1 cites·15 claims
- 3270US12350316B2IL7-IL 15 TxM compositions and methodsNANTBIO INC·Filed 2019·Granted Jul 8, 2025·0 cites·7 claims
- 3370US2025276040A1IL7-IL15 TxM Compositions and MethodsNANTBIO INC·Filed 2025·Application pending·0 cites
- 3469US11939585B2Multi-pulse transfection methods and cellsNANTBIO INC·Filed 2020·Granted Mar 26, 2024·0 cites·16 claims
- 3568US12280092B2Reprogrammed T cell-like NK cellsNANTBIO INC·Filed 2019·Granted Apr 22, 2025·0 cites·5 claims
- 3668US11773158B2Method of treatment of a tumor with an IL-8 antibodyNANTBIO INC·Filed 2020·Granted Oct 3, 2023·0 cites·12 claims
- 3768US11773187B2Enhanced immunogenicity for GPI-anchored antigensNANTBIO INC·Filed 2019·Granted Oct 3, 2023·0 cites·6 claims
- 3868US11672873B1Anti-B7-H4 antibodies and methodsNANTBIO INC·Filed 2020·Granted Jun 13, 2023·0 cites·20 claims
- 3968US10736884B2Compositions and methods of Rit1 inhibitionNANTBIO INC·Filed 2019·Granted Aug 11, 2020·0 cites·1 claims
- 4068US2024358760A1Primary T-Cell ExpansionNANTBIO INC·Filed 2024·Application pending·0 cites
- 4168US2023039169A1Modified EC7 Cells Having Low Toxicity to Viral Production PayloadsNANTBIO INC·Filed 2022·Application pending·0 cites
- 4266US2024124598A1Anti-CD30 monoclonal antibodies and chimeric antigen receptorsNANTBIO INC·Filed 2023·Application pending·0 cites
- 4365US11814436B2Anti-CD30 monoclonal antibodies and chimeric antigen receptorsNANTBIO INC·Filed 2022·Granted Nov 14, 2023·0 cites·18 claims
- 4465US2025179217A1Enhanced Immunogenicity For GPI-anchored AntigensNANTBIO INC·Filed 2025·Application pending·0 cites
- 4564US12098177B2Targeted IL-12 treatments and methods to stimulate haNK and NK92mi cellsNANTBIO INC·Filed 2019·Granted Sep 24, 2024·0 cites·17 claims
- 4664US12019067B2Interferometry based systems to detect small mass changes of an object in a solutionNANTBIO INC·Filed 2021·Granted Jun 25, 2024·0 cites·11 claims
- 4763US2024352533A1Monocarboxylic Acid Transporter 4 as a Biomarker for Hypoxia Driven Tumor Growth and TreatmentNANTBIO INC·Filed 2024·Application pending·0 cites
- 4862US12252525B2Chimeric T cell receptors, nucleic acids, and methods of making and using the sameNANTBIO INC·Filed 2021·Granted Mar 18, 2025·0 cites·27 claims
- 4962US12053512B2Method of validating the triggering of an immune response to a neoepitope of a tumor with t-cellsNANTBIO INC·Filed 2017·Granted Aug 6, 2024·0 cites·11 claims
- 5062US10668076B1Compositions and methods of targeting mutant K-RasNANTBIO INC·Filed 2017·Granted Jun 2, 2020·0 cites·8 claims
Showing the top 50 of 79 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →